Literature DB >> 20583971

Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.

Masayoshi Takeuchi1, Jun-ichi Takino, Sho-ichi Yamagishi.   

Abstract

Diabetic vascular complications are leading causes of acquired blindness, end-stage renal failure, a variety of neuropathies, and accelerated atherosclerosis, which may be involved in the disabilities and high mortality rates suffered by diabetic patients. Continuous hyperglycemia is involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic pathways, and numerous hyperglycemia-induced metabolic and hemodynamic conditions exist, including increased generation of various types of advanced glycation end-products (AGEs). Recently, we demonstrated that glyceraldehyde-derived AGEs (Glycer-AGEs), the predominant components of toxic AGEs (TAGE), play an important role in the pathogenesis of angiopathy in diabetic patients. Moreover, a growing body of evidence suggests that the interaction of TAGE with the receptor for AGEs (RAGE) alters intracellular signaling, gene expression, and the release of pro-inflammatory molecules and elicits oxidative stress generation in numerous types of cells, all of which may contribute to the pathological changes observed in diabetic vascular complications. Therefore, the inhibition of TAGE formation, blockade of TAGE-RAGE interaction, and the suppression of RAGE expression or its downstream pathways are promising targets for therapeutic interventions against diabetic vascular complications. In this review, we discuss the pathophysiological role of the TAGE-RAGE-oxidative stress system and related therapeutic interventions for preventing the development and progression of diabetic vascular complications.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583971     DOI: 10.2174/1389450111009011468

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  33 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

Review 2.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

3.  Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial).

Authors:  Mitsuhiro Shimomura; Jun-Ichi Oyama; Masayoshi Takeuchi; Yoshisato Shibata; Yusuke Yamamoto; Tomohiro Kawasaki; Hiroshi Komoda; Kazuhisa Kodama; Masashi Sakuma; Shigeru Toyoda; Yohei Inoue; Daigo Mine; Masahiro Natsuaki; Aiko Komatsu; Yutaka Hikichi; Sho-Ichi Yamagishi; Teruo Inoue; Koichi Node
Journal:  Heart Vessels       Date:  2015-12-23       Impact factor: 2.037

4.  Ethanol extracts from Portulaca oleracea L. attenuated ischemia/reperfusion induced rat neural injury through inhibition of HMGB1 induced inflammation.

Authors:  Chenggang Zheng; Chen Liu; Wanyin Wang; Gusheng Tang; Liwei Dong; Juan Zhou; Zhengrong Zhong
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

5.  Advanced glycation end-products reduce lipopolysaccharide uptake by macrophages.

Authors:  Atsuhiro Kitaura; Takashi Nishinaka; Shinichi Hamasaki; Omer Faruk Hatipoglu; Hidenori Wake; Masahiro Nishibori; Shuji Mori; Shinichi Nakao; Hideo Takahashi
Journal:  PLoS One       Date:  2021-01-25       Impact factor: 3.240

Review 6.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

7.  Anti-inflammatory effect of AMPK signaling pathway in rat model of diabetic neuropathy.

Authors:  Amin Hasanvand; Hossein Amini-Khoei; Mohammad-Reza Hadian; Alireza Abdollahi; Seyed Mohammad Tavangar; Ahmad Reza Dehpour; Elika Semiei; Shahram Ejtemaei Mehr
Journal:  Inflammopharmacology       Date:  2016-08-09       Impact factor: 4.473

Review 8.  Vascular Impairment of Epineurial Arterioles of the Sciatic Nerve: Implications for Diabetic Peripheral Neuropathy.

Authors:  Mark A Yorek
Journal:  Rev Diabet Stud       Date:  2015-08-10

9.  Advanced glycation end products accelerate rat vascular calcification through RAGE/oxidative stress.

Authors:  Qin Wei; Xiaomei Ren; Yibo Jiang; Hong Jin; Naifeng Liu; Jie Li
Journal:  BMC Cardiovasc Disord       Date:  2013-03-05       Impact factor: 2.298

10.  High-mobility group box-1 induces decreased brain-derived neurotrophic factor-mediated neuroprotection in the diabetic retina.

Authors:  Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Mohammad Mairaj Siddiquei; Abdullah S Al-Kharashi; Dustan Kangave; Ghulam Mohammad
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.